We just received data on a new analyst forecast for $INCY. Evan Seigerman from BMO Capital set a price target of 94.0 for INCY.
To track analyst ratings and price targets for $INCY, check out Quiver Quantitative's $INCY forecast page.
Should you buy $INCY?
Some analysts are better than others. To view the past performance of BMO Capital, check out Quiver’s Analyst Ratings dashboard. You can also see Quiver’s Analyst Buys Strategy, which uses a proprietary method to track the companies being recommended by the top Wall Street analysts.
$INCY Price Targets
Multiple analysts have issued price targets for $INCY recently. We have seen 14 analysts offer price targets for $INCY in the last 6 months, with a median target of $100.0.
Here are some recent targets:
- Evan Seigerman from BMO Capital set a target price of $94.0 on 06/22/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $140.0 on 06/09/2026
- Jeffrey Walch from Bernstein set a target price of $99.0 on 05/22/2026
- Stephen Willey from Stifel set a target price of $123.0 on 04/29/2026
- Jay Olson from Oppenheimer set a target price of $90.0 on 04/29/2026
- Ashwani Verma from UBS set a target price of $94.0 on 03/25/2026
- Faisal Khurshid from Jefferies set a target price of $94.0 on 03/16/2026
$INCY Insider Trading Activity
$INCY insiders have traded $INCY stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $INCY stock by insiders over the last 6 months:
- PABLO J CAGNONI (President, Global Head of R&D) has made 0 purchases and 3 sales selling 56,002 shares for an estimated $5,444,331.
- STEVEN H STEIN (EVP & Chief Medical Officer) sold 15,634 shares for an estimated $1,589,977
- MOHAMED KHAIRIE ISSA (EVP, Head of US Oncology) sold 10,856 shares for an estimated $1,184,063
- THOMAS TRAY (Principal Accounting Officer) has made 0 purchases and 2 sales selling 4,690 shares for an estimated $463,564.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$INCY Revenue
$INCY had revenues of $1.3B in Q1 2026. This is an increase of 20.87% from the same period in the prior year.
You can track INCY financials on Quiver Quantitative's INCY stock page.
You can access data on INCY stock through the Quiver Quantitative API.
$INCY Hedge Fund Activity
We have seen 420 institutional investors add shares of $INCY stock to their portfolio, and 414 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 2,526,758 shares (+341.7%) to their portfolio in Q1 2026, for an estimated $237,818,462
- PACER ADVISORS, INC. removed 1,248,642 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $123,328,370
- GOLDMAN SACHS GROUP INC added 1,067,757 shares (+83.2%) to their portfolio in Q1 2026, for an estimated $100,497,288
- DODGE & COX removed 1,009,386 shares (-7.6%) from their portfolio in Q1 2026, for an estimated $95,003,410
- AQR CAPITAL MANAGEMENT LLC removed 912,094 shares (-13.6%) from their portfolio in Q1 2026, for an estimated $85,846,287
- MAN GROUP PLC removed 834,218 shares (-43.1%) from their portfolio in Q4 2025, for an estimated $82,395,711
- SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) removed 754,116 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $70,977,397
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
